Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors.

Trial Profile

Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2014

At a glance

  • Drugs RG 7356 (Primary)
  • Indications Head and neck cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 24 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
    • 03 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Mar 2014as reported by ClinicalTrial.gov record.
    • 03 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top